Zobrazeno 1 - 10
of 1 175
pro vyhledávání: '"G Strittmatter"'
Publikováno v:
PLoS Genetics, Vol 17, Iss 7, p e1009708 (2021)
The TMPRSS2/ERG gene rearrangement occurs in 50% of prostate tumors and results in expression of the transcription factor ERG, which is normally silent in prostate cells. ERG expression promotes prostate tumor formation and luminal epithelial cell fa
Externí odkaz:
https://doaj.org/article/afec4a57568441b48b49b4d306cf744d
Publikováno v:
Value in Health. 25:S95
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8cad9100e5641923a716f5a3b963288
https://doi.org/10.1016/j.jval.2022.09.464
https://doi.org/10.1016/j.jval.2022.09.464
Publikováno v:
Advances in experimental medicine and biology. 1210
Prostate cancer is unique among carcinomas in that a fusion gene created by a chromosomal rearrangement is a common driver of the disease. The TMPRSS2/ERG rearrangement drives aberrant expression of the ETS family transcription factor ERG in 50% of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5280e35a54ea297f599eb54a5fb74321
https://pubmed.ncbi.nlm.nih.gov/31900919
https://pubmed.ncbi.nlm.nih.gov/31900919
Publikováno v:
PLoS Genetics
PLoS Genetics, Vol 17, Iss 7, p e1009708 (2021)
PLoS Genetics, Vol 17, Iss 7, p e1009708 (2021)
The TMPRSS2/ERG gene rearrangement occurs in 50% of prostate tumors and results in expression of the transcription factor ERG, which is normally silent in prostate cells. ERG expression promotes prostate tumor formation and luminal epithelial cell fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9701f0bc4d61828478412eac6a7c50a6
https://doi.org/10.1371/journal.pgen.1009708
https://doi.org/10.1371/journal.pgen.1009708
Publikováno v:
Advances in Experimental Medicine and Biology ISBN: 9783030326555
Prostate cancer is unique among carcinomas in that a fusion gene created by a chromosomal rearrangement is a common driver of the disease. The TMPRSS2/ERG rearrangement drives aberrant expression of the ETS family transcription factor ERG in 50% of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4905ee2fd2f65f73a1125ec79f7cf55
https://doi.org/10.1007/978-3-030-32656-2_18
https://doi.org/10.1007/978-3-030-32656-2_18
Publikováno v:
Cancer Research. 79:5257-5257
The TMPRSS2-ERG re-arrangement occurs in ~50% of prostate cancers and results in androgen driven aberrant expression of the transcription factor ERG. ERG acts as an oncogene in the prostate and activates a transcriptional program which results in cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11efb8c18a54c1a2de824e789b025dac
https://doi.org/10.1158/1538-7445.am2019-5257
https://doi.org/10.1158/1538-7445.am2019-5257
Autor:
Peter C. Hollenhorst, Vivekananda Kedage, Brady G. Strittmatter, Taylor R. Nicholas, Travis J. Jerde, Nagarathinam Selvaraj, Justin A. Budka
Publikováno v:
Cancer Research. 78:A023-A023
More than one-half of prostate tumors have a chromosomal rearrangement that results in the overexpression of an oncogenic ETS family transcription factor. The most common fusion, TMPRSS2/ERG, results in expression of ERG, a protein that is not normal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::901fb9fe8813bec80bd420a1b0569feb
https://doi.org/10.1158/1538-7445.prca2017-a023
https://doi.org/10.1158/1538-7445.prca2017-a023
Publikováno v:
The Journal of biological chemistry. 292(42)
In ∼50% of prostate cancers, chromosomal rearrangements cause the fusion of the promoter and 5′-UTR of the androgen-regulated TMPRSS2 (transmembrane protease, serine 2) gene to the open reading frame of ERG, encoding an ETS family transcription f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dba403f4f77e000559ea684de5c55c57
https://pubmed.ncbi.nlm.nih.gov/28887309
https://pubmed.ncbi.nlm.nih.gov/28887309
Publikováno v:
Value in Health. 22:S476
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f40b960a9da17ea5ae414f37fb7b123
https://doi.org/10.1016/j.jval.2019.09.404
https://doi.org/10.1016/j.jval.2019.09.404
Autor:
G. Strittmatter, M. Klein, C. Hallermann, J. Atzpodien, A. Krause-Bergmann, H.-J. Schulze, G. Brunner, G. Brodner
Publikováno v:
best practice onkologie. 4:4-22
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::567f5cc99cc0359f0119f34b158fbc6c
https://doi.org/10.1007/s11654-009-0186-4
https://doi.org/10.1007/s11654-009-0186-4